BD is recalling hundreds of thousands of its Alaris infusion pumps and vital sign monitors due to multiple system faults, including software- and user-related issues. According to the FDA, the errors ...
CareFusion Alaris(R) Infusion System Recognized as One of the 'Best All-Around' Pumps In KLAS Report
SAN DIEGO, April 20 A new report from KLAS, an independent health care vendor research firm, concluded the CareFusion (NYSE: CFN) Alaris® System is one of the "best all-around" infusion pump options ...
Becton, Dickinson and Company’s BDX, or popularly known as BD, initiated the recall of its infusion pumps last month after customer reports indicated software issues, potentially leading to inaccurate ...
PEORIA — On any given day, nurses provide compassionate, and, often, life-saving care to their patients. Sometimes that care can have a worldwide impact because of how health care — and those who work ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted 510(k) clearance to Becton Dickinson’s updated Alaris infusion pump, allowing the company to ...
WellSpan Health and CareFusion, a BD company (NYSE: BDX), today announced the successful implementation of the Alaris ® System across all four WellSpan hospitals, with WellSpan York Hospital becoming ...
The U.S. FDA said that BD (NYSE:BDX) has expanded its Class I voluntary recall to inform customers about the worst-case performance of the BD Alaris Pump Module model 8100 when used with certain ...
This technological achievement takes patient care and safety to a new level. ATLANTA, March 21, 2017 /PRNewswire-USNewswire/ -- Grady is proud to be Metro Atlanta's first hospital to successfully ...
Washington, D.C.--(Newsfile Corp. - December 16, 2024) - The Securities and Exchange Commission today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device ...
CareFusion Corporation has initiated a class 1 recall of the Alaris PC unit model 8015 with software version 9.12 because of a voltage problem, according to the US Food and Drug Administration (FDA).
Becton Dickinson (BD) medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results